Introduction
The proliferation of High Deductible Health Plans (HDHPs) in the United States is predicated on the theory of "consumer-directed" healthcare. By increasing patient "skin in the game" through higher deductibles, these plans aim to incentivize cost-conscious behavior and reduce low-value healthcare utilization. However, the effectiveness of this model is questionable for populations with complex, chronic conditions where care is often medically necessary rather than discretionary. This study investigates the impact of HDHP offerings on healthcare spending for individuals managing comorbid Substance Use Disorder (SUD) and Cardiovascular Disease (CVD).
Methods
Researchers utilized a quasi-experimental, intent-to-treat (ITT) design with a difference-in-differences (DiD) approach to analyze a decade of insurance claims (2007–2017) from the Optum Labs Data Warehouse (OLDW). The study sample included 33,684 enrollee-years representing adults aged 18–64 with comorbid SUD (alcohol or opioid use disorder) and CVD (e.g., myocardial infarction, ischemic vascular disease).
To avoid selection bias inherent in individual plan choice, the "treatment" was defined as an employer's decision to offer an HDHP. Spending was analyzed using two-part models: a logit model to predict the probability of any spending, and a generalized linear model (gamma distribution, log link) to estimate spending amounts among users.
Results
The study found that the introduction of an HDHP offer did not lead to a statistically significant reduction in total healthcare spending across any category, including SUD-specific, CVD-specific, or general medical services.
While total system costs remained flat, the financial burden shifted significantly toward the patients. Out-of-pocket (OOP) spending increased substantially across all categories. Specifically, OOP costs for SUD-specific services rose by 21.1%, and SUD-specific medication OOP costs increased by 21.7%. CVD-specific OOP spending increased by 13.1%.
Discussion
The findings suggest that for high-need patients with comorbid SUD and CVD, healthcare demand is relatively inelastic. Unlike healthier populations who may reduce utilization in response to higher deductibles, these patients require continuous management to prevent acute crises. Consequently, HDHPs do not achieve systemic cost savings in this group; instead, they function as a cost-transfer mechanism from insurers to vulnerable patients.
The 21% increase in OOP costs for SUD services is particularly concerning given the ongoing overdose crisis. Increasing financial barriers to treatment for substance use disorders may exacerbate health inequities and lead to adverse clinical outcomes in the long term. Future research should examine whether these increased costs eventually lead to deferred care and higher rates of emergency department visits or mortality.
Summary updated